Bethesda, Maryland 20892

  • Infectious Diseases

Purpose:

This study will examine the effects of HIV infection on substances produced by immune cells that increase or decrease HIV infection. HIV-infected patients and healthy normal volunteers may be eligible for this study. Participants will be required to have a yearly medical evaluation, including blood tests for cell counts and chemistries, a blood or urine pregnancy test for women, and other laboratory tests as medically indicated or for research purposes. Participants will donate blood or reproductive fluids, or both. From 20 to 150 cc (4 to 30 teaspoonfuls) of blood will be drawn from the arm using a small needle. Participants may be asked to provide blood samples on more than one occasion over the course of the study. No more than 450 cc (less than 1 pint) of blood will be drawn during any 6-week period. Males will be given a private room for semen donation; fluid from females will be collected with a cotton swab after speculum insertion. Participants may also be asked to have a buccal swab. For this procedure, the inside of the cheek is gently scraped with a blunt-ended stick or brush to obtain cells (buccal mucosal cells). The tissues will be used for a variety of studies on the effects of HIV infection on factors that increase or decrease HIV infection. Some of the tissues collected for this study may also be used for the following tests: - Hepatitis screening Blood may be screened for different types of viral liver infections, such as hepatitis A, B, C, D, E, or G. - Genetic testing DNA from blood or cheek cells may be examined for mutations or deletions that affect chemokines, cytokines and a family of enzymes called caspases. Chemokines and cytokines are important mediators of the immune response. Alterations in the genes for some of these substances influence HIV infection. Caspases regulate the process of cell death, known as apoptosis. Caspase gene variations may determine the rate of cell death in HIV-infected persons, and therefore, the rate of HIV progression. Patients with abnormalities of any of these genes may be invited to join other studies of the role of genetic defects in HIV infection. - HLA testing Blood may be tested for HLA type a genetic marker of the immune system. These tests may be used to try to identify factors associated with the rate of progression of HIV disease or related conditions. Determining HLA type is necessary to be able to perform certain research studies. Some HLA types have been associated with an increased risk of certain diseases like arthritis and other rheumatologic problems.


Study summary:

We are studying virologic and/or immunologic parameters of HIV infection and other infectious or non-infectious immune deficiency diseases in order to better understand the pathogenesis of HIV. Because of the lack of an adequate animal model it is generally necessary to utilize human peripheral blood cells for studying aspects of either in vivo or in vitro HIV infection. We wish to be able to continue to elucidate many pathogenic aspects of HIV infection in relation to other infectious or non-infectious immune regulation and dysregulation using human peripheral blood mononuclear cells as a model.


Criteria:

- INCLUSION CRITERIA: - 18 years of age or older. - Adequate venous access. - Have a blood pressure less than or equal to 180/100: pulse rate 50-100, unless a lower pulse rate is considered normal for the volunteer. - Have adequate blood counts (HIV positive volunteers: hemoglobin greater than or equal to 9.0 g/dL, platelets greater than or equal to 50,000; HIV negative volunteers: hemoglobin greater than or equal to 9.0 g/dL, platelets greater than or equal to 50,000) - Be willing and able to provide written informed consent on screening, comply with study requirements and procedures, and comply with clinic policies - Willingness to allow blood samples to be used for future studies of HIV infection/pathogenesis, and undergo hepatitis screening EXCLUSION CRITERIA: - Pregnant and/or breastfeeding females. - Active substance abuse or history of prior substance abuse that may interfere with protocol compliance or compromise patient safety.


NCT ID:

NCT00001281


Primary Contact:

Principal Investigator
Susan Moir, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)

Catherine A Seamon, R.N.
Phone: (301) 402-3481
Email: cseamon@cc.nih.gov


Backup Contact:

Email: sm221a@nih.gov
Susan Moir, Ph.D.
Phone: (301) 402-4559


Location Contact:

Bethesda, Maryland 20892
United States

For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
Phone: 800-411-1222
Email: ccopr@nih.gov

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 27, 2022

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.